UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Clinical cancer research, 2007-09, Vol.13 (18), p.5544s-5548s

2007

Volltextzugriff (PDF)

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Clinical cancer research, 2010-02, Vol.16 (4), p.1191-1205

2010

Volltextzugriff (PDF)

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Clinical cancer research, 2008-12, Vol.14 (23), p.7884-7895

2008

Volltextzugriff (PDF)

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6680-6686

2000

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

JAMA oncology, 2024-09

2024

Volltextzugriff (PDF)

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

The oncologist (Dayton, Ohio), 2003-12, Vol.8 (S3), p.5-17

Rowinsky, Eric K.

2003

Volltextzugriff (PDF)

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Volltextzugriff (PDF)

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Clinical cancer research, 2010-11, Vol.16 (22), p.5591-5602

2010

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2016

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Clinical cancer research, 2008-07, Vol.14 (14), p.4484-4490

2008

Volltextzugriff (PDF)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Volltextzugriff (PDF)

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3854-3861

2005

Volltextzugriff (PDF)

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Clinical cancer research, 2011, Vol.17 (1), p.193-200

2011

Volltextzugriff (PDF)

Vascular endothelial growth factor receptor‐1 in human cancer

Cancer, 2010-02, Vol.116 (S4), p.1027-1032

2010

Volltextzugriff (PDF)

Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients

Clinical cancer research, 2003-07, Vol.9 (7), p.2478-2486

2003

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-05, Vol.15 (10), p.3591-3599

2009

Volltextzugriff (PDF)

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Cancer, 2010-02, Vol.116 (S4), p.1013-1017

2010

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Clinical cancer research, 2007-05, Vol.13 (9), p.2675-2683

2007

Volltextzugriff (PDF)

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Clinical cancer research, 2004-08, Vol.10 (15), p.5048-5057

2004

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(107)
Mit Volltextzugriff
(123)

Publikationsform

Artikel
(108)
Buchkapitel
(15)
Bücher
(2)

Sprache

Englisch
(125)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(106)
Science & Technology
(106)
Humans
(99)
Biological And Medical Sciences
(81)
Medical Sciences
(81)
Antineoplastic Agents
(79)
Pharmacology. Drug Treatments
(77)
Male
(68)
Female
(66)
Middle Aged
(66)
Adult
(62)
Aged
(62)
Neoplasms - Drug Therapy
(51)
Chemotherapy
(49)
Dose-Response Relationship, Drug
(40)
Drug Administration Schedule
(28)
Antineoplastic Agents - Therapeutic Use
(26)
Tumors
(26)
Antineoplastic Agents - Pharmacokinetics
(24)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

mTOR Inhibition for Cancer Therapy: Past, Present and Future

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

Vascular endothelial growth factor receptor‐1 in human cancer

Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Aktive Filter

Suchergebnisse filtern